Tanya B. Dorff

Oct 16, 2024 | nature.com | Tanya B. Dorff |Alicia K. Morgans

AbstractNovel therapies for metastatic castration-resistant prostate cancer (mCRPC) have improved patient outcomes. However, there is uncertainty on the optimal selection of therapeutic agents for subsequent lines of therapy. We conducted a comprehensive review of published evidence from pivotal clinical trials and recent guidelines for the treatment of mCRPC. We further identify gaps in knowledge and areas for future research.

Jul 6, 2024 | cancernetwork.com | Tanya B. Dorff

A first-in-human phase 1 trial (NCT03873805) investigated the safety and bioactivity of prostate stem cell antigen–directed CAR T cells for patients with metastatic castration-resistant prostate cancer. CancerNetwork® spoke with Tanya B. Dorff, MD, professor in the Department of Medical Oncology and Therapeutics Research and division chief of the Genitourinary Disease Program at City of Hope in Duarte, California, about what she hopes colleagues will take away from the results of the trial.

Jul 4, 2024 | cancernetwork.com | Tanya B. Dorff

Tanya B. Dorff, MD, professor in the Department of Medical Oncology and Therapeutics Research and division chief of the Genitourinary Disease Program at City of Hope in Duarte, California, spoke with CancerNetwork® about the results of a phase 1 trial (NCT03873805) evaluating the efficacy and adverse effects (AEs) of prostate stem cell antigen (PSCA)–directed CAR T cells in metastatic castration-resistant prostate cancer (CRPC).

Jun 21, 2024 | urotoday.com | Tanya B. Dorff

Read the Full Video TranscriptAndrea Miyahira: Hi, everyone. I'm Andrea Miyahira here at The Prostate Cancer Foundation. Joining me is Dr. Tanya Dorff, a professor at City of Hope. Dr. Dorff will present her group's recent paper, "PSCA CAR T Cell Therapy for Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Trial," that was published in Nature Medicine. Dr. Dorff, thank you for joining me and sharing your work with us today. Tanya Dorff: Pleasure to be here.

Apr 19, 2024 | nature.com | Tanya B. Dorff |Riccardo Lombardo

AbstractThe systematic review by Saouli et al. investigates the role of radical prostatectomy (RP) in managing oligometastatic prostate cancer (omPCa) [1]. They analyzed the existing literature to assess the oncological and functional outcomes of RP for these patients. RP is feasible and has an acceptable risk of complications.